Disulfiram: Mechanism, Clinical Applications, and Emerging Research > 자유게시판

• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Disulfiram, sold under the trade name Antabuse, is a medication primarily used to treat chronic alcoholism by producing an acute sensitivity to ethanol. First synthesized in the 1920s and approved by the U.S. Food and Drug Administration in 1951, it has remained a cornerstone of aversion therapy for alcohol use disorder. This report provides a concise overview of disulfiram’s pharmacology, clinical use, adverse effects, and recent investigations into its potential for other conditions.

Mechanism of Action

Disulfiram acts by irreversibly inhibiting aldehyde dehydrogenase (ALDH), an enzyme in the liver that catalyzes the oxidation of acetaldehyde to acetate during ethanol metabolism. Normally, ethanol is first oxidized to acetaldehyde by alcohol dehydrogenase (ADH), then rapidly converted to harmless acetate by ALDH. When disulfiram blocks ALDH, acetaldehyde accumulates in the blood and tissues, leading to the disulfiram-ethanol reaction (DER). This reaction is characterized by flushing, throbbing headache, nausea, vomiting, sweating, palpitations, hyperventilation, tachycardia, and hypotension. The intense discomfort serves as a strong deterrent to alcohol consumption. The inhibition of ALDH is irreversible; new enzyme synthesis is required for recovery, which typically takes up to two weeks after the last disulfiram dose. Additionally, disulfiram chelates copper and zinc, which may contribute to its inhibition of dopamine beta-hydroxylase, affecting catecholamine metabolism.

Clinical Use in Alcohol Dependence

Disulfiram is indicated for patients with alcohol dependence who have expressed a desire to maintain sobriety and are motivated to participate in a comprehensive treatment program including psychosocial support. It is not a cure for alcoholism but a pharmacological adjunct that reinforces abstinence by creating a powerful negative association with drinking. The typical maintenance dose is 250 mg once daily, though some patients require 125 mg to 500 mg. Treatment should not begin until at least 12 hours after the last alcohol consumption. The drug is generally continued for several months to years, depending on clinical response. Compliance is a major challenge; supervised administration (e.g., by a spouse, family member, or clinic) improves outcomes. Efficacy trials show mixed results, with significant benefit primarily in patients who are highly motivated or supervised. Systematic reviews indicate that disulfiram reduces the number of drinking days and increases abstinence rates when adherence is ensured. However, compared to naltrexone or acamprosate, it has fallen out of favor in some settings due to the aversive nature and risk of severe reactions.

Disulfiram-Ethanol Reaction (DER)

The severity of DER depends on the dose of disulfiram, the amount of ethanol consumed, and individual patient factors. Mild to moderate reactions occur with 5-15 mL of 80-proof alcohol and are self-limiting, lasting 30 minutes to a few hours. Severe reactions can involve respiratory depression, cardiovascular collapse, cardiac arrhythmias, myocardial infarction, congestive heart failure, unconsciousness, convulsions, and even death. Thus, patients must be thoroughly educated to avoid all forms of alcohol, including alcohol-containing foods, medications (e.g., cough syrups, mouthwash, tonics), and topical products (e.g., aftershave, hand sanitizers) that may be absorbed through the skin. Emergency management includes supportive care, oxygen, intravenous fluids, vasopressors for hypotension, and intravenous antihistamines for severe flushing. Propranolol or other beta-blockers may be used to control tachycardia and hypertension.

Adverse Effects and Contraindications

Besides the intended DER, disulfiram can cause side effects even without alcohol. Common adverse effects include drowsiness, headache, metallic or garlic-like aftertaste, mild fatigue, and skin eruptions. In rare cases, disulfiram can cause hepatotoxicity, ranging from transient elevation of liver enzymes to fulminant hepatic failure. Liver function tests are recommended before and during therapy. Peripheral neuropathy and optic neuritis have also been reported, particularly with prolonged high doses. Disulfiram is contraindicated in patients with severe myocardial disease, coronary occlusion, psychosis, hypersensitivity to thiuram compounds, and in those who have recently taken metronidazole, paraldehyde, or alcohol. It should not be given to patients in a state of alcohol intoxication or without their full knowledge and consent. Pregnancy and breastfeeding are relative contraindications; risk-benefit assessment is necessary.

Drug Interactions

Disulfiram inhibits several cytochrome P450 enzymes, notably CYP2E1 and CYP3A4. It can increase the plasma concentrations of drugs such as warfarin, phenytoin, benzodiazepines (especially chlordiazepoxide and diazepam), tricyclic antidepressants, and theophylline. Concurrent use of isoniazid or metronidazole may cause psychotic reactions. Patients should be monitored for enhanced effects or toxicity when these drugs are co-prescribed.

Emerging Research and Non-Approved Uses

In recent decades, disulfiram has attracted attention for potential use beyond alcohol aversion. Preclinical studies and early clinical trials suggest anticancer activity through multiple mechanisms: inhibition of nuclear factor-kappa B (NF-κB), induction of oxidative stress, proteasome inhibition, and copper-dependent cytotoxicity. A number of phase II/III trials have investigated disulfiram in combination with chemotherapy for Aceon 2mg glioblastoma, breast cancer, melanoma, and lung cancer. Results are promising but not yet definitive; a 2020 meta-analysis found a trend toward improved overall survival in certain subgroups. Additionally, disulfiram is being studied for its ability to inhibit brain aldehyde dehydrogenase and dopamine beta-hydroxylase, which may reduce cocaine craving and relapse. Small trials in cocaine dependence have shown modest reduction in use, but larger trials are lacking. Other areas of investigation include HIV (it may activate latent HIV reservoirs in combination with other agents) and parasitic infections (e.g., giardiasis, leishmaniasis). However, these uses remain experimental and are not approved by regulatory authorities.

Conclusion

Disulfiram remains a unique and powerful adjunct for the treatment of alcohol dependence when used in a supervised, motivated patient population. Its mechanism of action, based on aversion to ethanol, differs from other pharmacotherapies and can be highly effective for selected individuals. The risk of severe adverse reactions, especially DER and hepatotoxicity, mandates careful patient selection and monitoring. Ongoing research into disulfiram’s anticancer, anti-addictive, and antimicrobial properties may expand its therapeutic utility, but rigorous clinical validation is still needed. Healthcare providers should weigh potential benefits and harms, ensure patient understanding and consent, and integrate disulfiram into a comprehensive treatment plan for alcohol use disorder.